We describe 9 cases of precursor B-cell lymphoblastic lymphoma (LYL) 
Lymphoblastic lymphoma (LYL) is a neoplasm of immature lymphoid cells. The cells are morphologically identical to the lymphoblasts of acute lymphoblastic leukemia (ALL). Commonly used criteria to distinguish LYL from ALL are as follows: (1) manifestation as bulky masses in solid organs; (2) focal (<25%) or absent bone marrow involvement; and (3) absence of peripheral blood involvement. 1 Unlike ALL, in which 85% of tumors are of B-cell lineage, 2 no more than 10% of LYLs express B-cell markers. 3 There are approximately 100 immunophenotyped cases of precursor B-cell LYLs reported in the literature; most are single case reports or very small series. Several cases reported as LYL do not conform to the diagnostic criteria for this disease. 27, 28 The proposed Revised European-American classification system of lymphoid neoplasms (REAL) has merged the categories of precursor B-cell ALL and LYL into a single entity, 29 but the existing data on LYL are insufficient to validate this proposal. In this report, we describe 9 cases of precursor B-cell LYL and comprehensively review the literature to better characterize this uncommon neoplasm. All 9 cases selected for the present study lacked evidence of blood and bone marrow involvement.
Materials and Methods
A retrospective search of the hematopathology archives of Parkland Memorial Hospital and Children's Medical Center (affiliate hospitals of University of Texas Southwestern Medical Center, Dallas) from November 10, 1989 , through May 10, 2000, yielded 9 cases of precursor B-cell LYL lacking evidence of blood and bone marrow involvement. Clinical data were retrieved from the patient charts. Histologic sections were available for review in all cases.
Fresh specimens of tissue or blood were processed according to a variety of protocols depending on the source of the specimen and the period during which it was obtained. The method of tissue preparation for flow cytometry from fresh tumor samples has been described previously. 30 All specimens analyzed at the University of Texas Southwestern Medical Center were studied on a FACSort (3-color) or a FACSCalibur (4-color) flow cytometer (Becton Dickinson [BD] Immunocytometry Systems, San Jose, CA), and data were analyzed with Paint-A-Gate software (Verity House, Topsham, ME). All normal and neoplastic populations within a given sample were characterized. Antigen expression on abnormal populations was compared with appropriate isotypic controls and negative and positive populations in a given tube. Antigen positivity was defined as a discrete population shift relative to the same population in the isotypic control tube. Assessments of intensity of antigen expression were qualitative and based on accumulated laboratory experience with individual antibodies in normal and neoplastic cell populations.
Four-color flow cytometric analysis of fresh tumor tissue was performed in 5 cases (1, 3-5, and 7) and 3-color analysis in 1 (case 8); for case 2, diagnosed in 1989, 1-color flow cytometric analysis was performed at a centralized POG (Pediatric Oncology Group) institution (POG protocol 8719). Various combinations of tissue panels were used with the following antibodies: CD2 (55.2), CD3 (SK7), CD4 (SK3), CD5 (L17F12), CD7 (4H9), CD8 (SK1), CD10 (W8E7), CD11b (D12), CD11c (S-HCL-2), CD14 (MφP9), CD19 (SJ25C1), CD20 (L27), CD22 (S-HCL-1), CD34 (MY10), CD38 (HB7), CD45 (2D1), CD45RO (UCHL-1), CD56 (MY31), monoclonal kappa (TB28-2), and monoclonal lambda (I-155-2), all from BD Immunocytometry Systems; CD23 (B6), CD45RA (2H4LDH11LDB9), FMC7 (FMC7), polyclonal kappa (polyclonal goat IgG), and polyclonal lambda (polyclonal goat IgG), all from Coulter-Immunotech, Hialeah, FL; CD33 (4D3, Caltag, Burlingame, CA); CD30 (BerH2, DAKO, Carpinteria, CA); and terminal deoxynucleotidyl transferase (TdT; HT-1, HT-3, HT-4, DAKO). Immunophenotyping of the bone marrow aspirate at diagnosis was performed with 4-color analysis in cases 1, 3-7, and 9; 3-color analysis in case 8; and 1-color analysis in case 2.
In 2 cases (6 and 9), fresh tumor tissue was unavailable, and immunohistochemical analysis was performed on paraffin sections using various antibodies from the following panel ( mean and median ages at diagnosis were 17 and 10 years, respectively (range, 4-71 years). The sites of presentation were superficial nodal disease (4 cases); cutaneous lesions (2 cases); and ovarian, retroperitoneal, and tonsillar primary (1 case each). The head and neck region was the initial site of diagnosis in 6 of 9 cases. According to the St Jude classification for non-Hodgkin lymphomas in children, 31 6 of 9 had limited stage disease (stage I or II), while 3 had stage III disease (Table 1) . ❚Table 2❚ summarizes the hematologic findings. None of the patients had cytopenias at the time of diagnosis. Morphologically evident bone marrow and peripheral blood involvement was absent in all cases, and cerebrospinal fluid examination was negative in 8 cases. In case 3, mildly "suspicious" cells were observed in the initial lumbar puncture fluid but were not believed to be diagnostic of lymphoma involvement.
Histologic Features
Lymph node examination in 5 cases (including retroperitoneal nodes in case 7) and tonsillar and ovarian tissue in 1 case each showed diffuse effacement of architecture. Pericapsular extension was seen in lymph nodes. The architectural pattern of involvement by neoplastic cells was different in the 2 cases manifesting in the skin. In case 1, there was replacement of the papillary and reticular dermis by a strikingly nodular infiltrate that splayed the adnexal structures without effacing them. A well-demarcated grenz zone was seen, and the overlying epidermis was not ulcerated or infiltrated. While most of the cells constituting the infiltrate had lymphoblastic morphologic features, a minor component of mature lymphocytes was present. In case 6, a perivascular and periadnexal lymphoid infiltrate was observed that generally spared the papillary dermis and was more prominent in the deep dermis. In contrast with case 1, the majority of cells in the superficial areas of the biopsy specimen were mature lymphocytes; the lymphoblastic component was restricted to the subcutaneous fat.
The neoplastic population in all cases consisted of a monotonous population of medium-sized lymphoid cells, with high nuclear/cytoplasmic ratios, immature chromatin, and inconspicuous nucleoli ❚Image 1❚. The nuclear contours were round to slightly irregular in 1 case, mildly irregular in 7, and markedly irregular in 1. Moderate to marked mitotic activity was seen in all cases.
Immunophenotypic and Immunohistochemical Analysis
❚Table 3❚ summarizes the immunophenotypic and immunohistochemical analyses performed on the primary tumor tissues from the 9 patients. All cases expressed either TdT or CD34. Of the 7 cases examined by flow cytometry, TdT was expressed in 6. Partial CD34 expression was observed in 4 of 6 cases; the pan B-cell antigen CD19 was present in all 7. CD22 was positive in 6 of 6 cases, while CD20 was either partially positive (5 of 7) or negative (2 of 7). CD10 (CALLA [common acute lymphoblastic leukemia antigen]) expression was observed in 5 of 7 cases. HLA-DR and CD38 reactivity were present in 5 of 5 and 6 of 6 cases, respectively. CD23, FMC7, and surface light chain expression were absent in all cases. The T-cell antigens CD2, CD3, CD5, CD7, CD45RO, CD4, and CD8, as well as the myeloid antigens CD15 and CD33, were negative in all cases.
Immunohistochemical analysis in case 6 showed expression of TdT, CD45, CD79a, CD10, and CD43 and lack of CD20, CD3, CD5, CD8, CD56, TIA-1, and cyclin D1 expression. The neoplastic cells were bcl-2 positive and had a high proliferative index by MIB-1 labeling. Case 9 also was analyzed using a panel of immunohistochemical markers and demonstrated reactivity for TdT, CD45, and CD20, with lack of CD5, CD3, and cyclin D1 expression.
Cytogenetic Analysis
Fresh tumor tissue was submitted for cytogenetic analysis in 5 cases (1, 3, 5, 7, and 8) . In cases 1, 3, and 7, no growth was observed after 7-day cultures. In case 5, 
Clinical Outcome
❚Table 4❚ summarizes the therapy instituted and the most recent follow-up for the 9 patients. Six of the 7 children were treated with the DFW (Dallas-Fort Worth) II ALL protocol with induction by dexamethasone, vincristine, daunorubicin, and asparaginase over a 4-week period, followed by a consolidation phase using methotrexate and mercaptopurine. 33 The seventh pediatric patient was treated with the POG 8719 protocol that preceded DFW II at our institution. (See footnote to Table 4 ; detailed information on past and current POG protocols is present on the POG Web site at http://www.pog.ufl.edu/.) One adult patient (case 8) completed therapy, including 2 years of maintenance chemotherapy, and the second adult (case 9) is currently on a hyper-CVAD (cyclophosphamide, vincristine, doxorubicin, and dexamethasone) protocol 32 alternating with methotrexate and cytarabine. The median follow-up was 14 months (range, 2-129 months), and all patients are in complete remission.
Discussion
Although precursor B-cell LYL and ALL have been merged as a single entity in the new REAL classification, 29 the data on precursor B-cell LYL are limited to small series or isolated case reports. We report 9 cases of precursor B-cell LYL lacking blood and bone marrow involvement and a review of the literature. Inclusion criteria for the literature review were based on the Murphy criteria for diagnosis of LYL (<25% bone marrow involvement by lymphoma cells), because it often was impossible to distinguish cases with or without bone marrow involvement. We excluded single case reports 27, 28 and individual cases from larger series 4, 6, 9, 18 in which the extent of marrow involvement was not defined or was greater than 25%, as well as cases in which immunophenotyping of the neoplastic cells had not been performed. 34, 35 By these criteria, 105 cases including 9 from the present study were reviewed.
Age at diagnosis was available for 98 patients, of whom 63 (64%) were younger than 18 years ❚Table 5❚. Precursor Bcell LYL, like precursor B-cell ALL, 2,36 seems to be a disease of young people. The primary site was available for 103 cases. Approximately three fourths of the patients had disease in the skin (with or without adjacent nodal involvement), lymph nodes, or bone. The mediastinum was an uncommon site of presentation. Miscellaneous sites such as head and neck (parotid gland, Waldeyer ring), retroperitoneum, breast, ovary, brain, and soft tissues were the sites in ❚Image 1❚ (Case 1) Cheek mass. Uniform, medium-sized lymphoblasts with round to mildly irregular nuclei, fine chromatin, and inconspicuous nucleoli (H&E, ×330). All cases were immunophenotyped for at least one early B-cell antigen, in addition to other lineage-associated and activation markers. Since the cases spanned almost 2 decades, a variety of different B-and T-cell antibodies were used, including different clones directed against the same antigen. Lineage determination was performed on fresh frozen tissue, archival material, and cell suspensions; the results are tempered by methods, the sensitivity and specificity of different antibodies, and the tissues on which they were applied. ❚Table 6❚ summarizes the 9 most commonly examined antigens and the proportion of reactivity in LYL. Among the B-cell antigens, CD 19, CD79a, and CD10 were commonly expressed, while CD20 was expressed in almost two thirds of the cases. Ninety-two percent of cases expressed TdT, while 64% expressed CD34. Two important caveats emerged from the immunophenotyping data: CD45 (leukocyte common antigen [LCA]) was present in 62% of the cases, and in most instances it was dimly expressed; and CD 99 expression, presumed at one time to be specific for the Ewing family of tumors (EFTs), was seen in 75% of cases. The importance of these findings in the differential diagnosis of precursor B-cell LYL is discussed in the subsequent text.
The data on cytogenetic aberrations in precursor B-cell LYL are rudimentary, with only 8 karyotyped cases to the best of our knowledge ❚Table 7❚. Although the number of cases is small, hyperdiploidy does not seem to be as commonly observed as in precursor B-cell ALL. 2 Moreover, some of the characteristic structural cytogenetic changes such as the translocations (9;22), (1;19) , and (4;11) seen in precursor B-cell ALLs were not found. Significantly, 3 of the 8 cases had additional chromosome 21 material, one as a trisomy, one as a tetrasomy, and the third as an add (21) (q22). 23 Trisomy and polysomy of chromosome 21 are wellcharacterized, nonrandom changes seen in ALLs. 38 The 21q22 region is involved in the (12;21) translocation, resulting in the TEL/AML1 fusion gene, and trisomy 21 has been reported to be the most common secondary aberration in TEL/AML1-positive ALL. 38 Presently, the incidence of t(12;21) rearrangement in precursor B-cell LYL is unknown. The differential diagnosis of precursor B-cell LYL includes T-cell LYL and the blastoid variant of mantle cell lymphoma, as well as malignant neoplasms of the small blue cell category, such as EFTs. Although the mean ages for precursor B-cell LYL and T-cell LYL are virtually identical, T-cell LYL has a much higher proportion of cases occurring in the mediastinum, 50% to 65%, compared with 4% for precursor B-cell LYL. 25, 39 Most T-cell LYLs also express TdT and CD99, [24] [25] [26] while up to a third express CD10. 2 However, reactivity for at least 1 pan T-cell marker (CD2, CD3, CD5, CD7) is present in all cases of T-cell LYL. The blastoid variant of mantle cell lymphoma is also in the differential diagnosis of a "lymphoblastoid" malignant neoplasm. Histologic sections from a blastoid variant of mantle cell lymphoma may look virtually identical to B-or T-cell LYL. 20, 25 The blastoid variant of mantle cell lymphoma manifests in older people in their sixth or seventh decades of life, with a strong male predominance. 40 The neoplastic cells express CD5, FMC7, cyclin D1, and surface immunoglobulin light chains but do not express the immature markers such as TdT and CD34. 41, 42 Rarely, follicular lymphomas have been reported to undergo blastic/blastoid transformation, with histologic features resembling LYL. 43 The history of previously diagnosed follicular lymphoma, presence of a (14;18) translocation, and lack of expression of immature antigens distinguish this rare entity from LYL.
Precursor B-cell LYLs can manifest as a primary bone lesion, 24, 26, 37 and EFTs need to be excluded because of overlapping patient populations. Both precursor B-and T-cell LYL express CD99, which at one time was thought to be unique to EFTs. 44 Moreover, only two thirds of precursor Bcell LYLs express CD45 (LCA), and, thus, a CD99+, LCAnegative tumor should not be equated with a diagnosis of EFT. Additional immunohistochemical stains such as TdT, CD34, or CD79a, which are negative in EFTs, are needed to exclude precursor B-cell LYL. 42 CD43 is another commonly expressed antigen found in both B-and T-cell LYLs that is not present in EFTs. 24 The demonstration of an (11;22) translocation or the EWS-FLI1 fusion product characteristic of EFTs is helpful in establishing the correct diagnosis.
The mode of therapy was available for 99 (94.3%) of 105 patients. All except 2 received combination chemotherapy with or without radiation therapy; 2 patients received local radiotherapy without chemotherapy. Thirty-eight (38%) of 99 patients were treated with pediatric or adult nonHodgkin lymphoma chemotherapy regimens and 29 (29%) of 99 by a variety of ALL protocols; details of multiagent chemotherapy were not available for the remaining 32 patients.
The median follow-up period was 26 months (range, 2-144 months) for the 81 (77.1%) of 105 patients for whom information was available (Table 5 ). Sixty of the 81 (74%) were alive with no evidence of disease at a median of 28 months (range, 2-144 months); 21 (26%) of 81 were dead of disease, with a median survival of 19 months (range, 2-72 months). Of the patients who died, 13 (62%) of 21 were adults, and 8 (38%) were children. Considering that adults represented a minority of cases, the disease seems to be more aggressive in older people, similar to precursor B-cell ALL. 45 To our knowledge, there have been no multicenter studies to evaluate survival in precursor B-cell LYL using consensus risk stratification or standard treatment protocols. However, based on the present cases and review of the literature, most patients with precursor B-cell LYL have a high rate of complete remission and favorable outcome (74% survival at a median follow-up of 26 months), similar to what has been reported for precursor B-cell ALL. 36, 46 Larger studies would be useful to define high-risk criteria in precursor B-cell LYL and to determine the most appropriate therapy.
A comparison of the common clinicopathologic features of precursor B-cell LYL and ALL are given in ❚Table 8❚. Discordant features between the two entities included incidence and frequency of skin involvement. Although very few cases of precursor B-cell LYL have been karyotyped, additional 21q material may possibly emerge as a recurring cytogenetic anomaly, while hyperdiploidy and translocations observed in ALL (12;21, 1;19, 9;22) may be less frequent. There were several similarities between precursor B-cell LYL and ALL, such as the high proportion of cases in childhood, low frequency of mediastinal involvement, similar incidence of central nervous system disease at diagnosis, and common immunophenotypic profile. We report the clinical, pathologic, immunophenotypic, and cytogenetic features in 9 cases of precursor B-cell LYL with no evidence of bone marrow or peripheral blood involvement, and we describe our review of the literature. Our findings indicate that precursor B-cell LYL is an uncommon disease that has many clinicopathologic features similar to precursor B-cell ALL, including some that are distinct. While the unification of precursor B-cell LYL and ALL into a single entity in the REAL classification seems appropriate at present, a multicenter collaborative study to confirm this conclusion may be warranted in the future. 
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